MANAGEMENT OF ANAEMIA IN PATIENTS ON DIALYSIS Philip N. Jeremiah Bee Boon Cheak Ghazali B Ahmad Lim Soo Kun Zawawi B Nordin Source: 20 th MDTR Report 2012,

Slides:



Advertisements
Similar presentations
UK Renal Registry 13th Annual Report Figure 12.1: Median height z-scores for transplant patients in 2009.
Advertisements

CHAPTER 7: Nutritional Status on Dialysis Abdul Halim B Abd Gafor Winnie Chee Siew Swee Tilakavati Karupaiah Koh Keng Hee Ahmad Fauzi B Abd Rahman Source:
Update of Anemia management in chronic kidney disease What is still missing.
Chapter 3: Clinical Indicators and Preventive Care 2014 A NNUAL D ATA R EPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE.
Iron Repletion in ESRD Saleem Bharmal 2/9/10.
When Using DOPPS Slides. DOPPS Slide Use Guidelines.
A 3 A 3 A 3 A 3 B 3 B 3 B 3 B 3.
UK Renal Registry 17th Annual Report Figure 9.1. Median height z-scores for transplant patients
UK Renal Registry 16th Annual Report Figure Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2012.
UK Renal Registry 14th Annual Report Figure 8.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2010.
How to manage anaemia in HD patients
CHAPTER 12 Peritoneal Dialysis Sunita Bavanandan Lily Mushahar Anita Bhajan Manocha Source: 20 th MDTR Report 2012, NRR.
Chapter 4: Quality of life and rehabilitation outcomes of patients on Dialysis Liu Wen Jiun Chew Thian Fook Christopher Lim Thiam Seong Tan Wee Ming Yia.
Scottish Renal Registry Report 2009 Published by the Information Services Division (ISD Scotland), Common Services Agency for NHSScotland, 1 South Gyle.
CHAPTER 5: PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail Source: 21 st MDTR.
CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 21 st MDTR Report 2013, NRR.
CHAPTER 1: ALL RENAL REPLACEMENT THERAPY IN MALAYSIA Lim Yam Ngo Ong Loke Meng Goh Bak Leong Lee Day Guat Source: 20 th MDTR Report 2012, NRR.
INJECTAFER Pharmacokinetics (PK) and Pharmacodynamics (PD) Christy S. John, Ph.D Division of Clinical Pharmacology V Office of Clinical Pharmacology Division.
UK Renal Registry 10th Annual Report 2007 Fig 8.1 Median haemoglobin for incident dialysis patients at start of dialysis treatment.
CHAPTER 6: MANAGEMENT OF ANAEMIA IN PATIENTS ON DIALYSIS Philip N. Jeremiah Bee Boon Cheak Ghazali B Ahmad Lim Soo Kun Zawawi B Nordin Source: 21 st MDTR.
UK Renal Registry 15th Annual Report Figure 6.1. Median haemoglobin for incident dialysis patients at start of dialysis treatment in 2011.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 3: Clinical Indicators and Preventive Care.
© ANZDATA Registry Prevalence and Incidence End Stage Renal Failure - Australia ( ) Per Million Functioning Transplant (259) New Pts (82) Deaths.
CHAPTER 9: Chronic Kidney Disease – Mineral and Bone DisorderKok Lai Sun Ching Chen Hua Fan Kin Sing Rozina Ghazalli Liew Yew Fong Source: 21 st MDTR Report.
CHAPTER 8: Blood Pressure Control and Dyslipidaemia in Patients on Dialysis S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 21 st.
CHAPTER 11 Haemodialysis Practices Tan Chwee Choon Shahnaz Shah Firdaus Khan Rafidah Abdullah Norleen Bt Zulkarnain Sim Source: 20 th MDTR Report 2012,
CHAPTER 13 Renal Transplantation Goh Bak Leong Fan Kin Sing Rohan Malek Bin Dato’ Dr. Johan Rosnawati Yahya S. Prasad Menon Tan Si Yen Wong Hin Seng Source:
Chapter 1 ALL RENAL REPLACEMENT THERAPY IN MALAYSIA
Chapter 3 Death and Survival on Dialysis Wong Hin Seng Ong Loke Meng Source: 20 th MDTR Report 2012, NRR.
UK Renal Registry 15th Annual Report Figure 7.1. Median height z-scores for transplant patients
CHAPTER 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Source: 20 th MDTR Report 2012, NRR.
The use of Ferinject® (ferric carboxymaltase) in the treatment of iron deficiency in patients with renal anaemia Dr D Farrugia Dr S Ramakrishna E Gibson.
Date of download: 6/26/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Trends in Anemia Care in Older Patients Approaching.
CHAPTER 8: BLOOD PRESSURE CONTROL AND DYSLIPIDAEMIA S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 20 th MDTR Report 2012, NRR.
Figure 3.1 ESRD clinical indicators, CROWNWeb data, December 2015
Medical Directorate, National Kidney Foundation, Singapore
Kamyar Kalantar-Zadeh  Kidney International 
Mansoura International Hospital Mansoura International Hospital
Algorithm for management of anemia of CKD in adults
Copyright © 2002 American Medical Association. All rights reserved.
Figure 5. Liver-fatty acid binding protein concentration in human serum. The serum L-FABP levels of the healthy control group (n=63), renal diseases of.
Chapter 2: Clinical Indicators and Preventive Care
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
CHAPTER 5 Paediatric Renal Replacement Therapy
Table 4.1: Cumulative distribution of QoL-Index score in relation to dialysis modality, all dialysis patients
CHAPTER 7 Nutritional Status on Dialysis
CHAPTER 11: Haemodialysis Practices
Iron status and iron supplementation in peritoneal dialysis patients
CHAPTER 3 Death and Survival on Dialysis
Volume 2: End-Stage Renal Disease
A Six-hour Hemodialysis Without a Significant Increase in Dialysis Dose, as Judged by Kt/V, Can Reduce the Dosage of Erythropoietin Department of Kidney.
Navneet S. Majhail, Todd DeFor, Hillard M. Lazarus, Linda J. Burns 
CHAPTER 3 DEATHS Stephen McDonald 2012 Annual Report—35th Edition
CHAPTER 9 Chronic Kidney Disease – Mineral and Bone Disorder
Christopher Lim Thiam Seong
CHAPTER 10 Hepatitis on Dialysis
Volume 54, Issue 2, Pages (August 1998)
Kamyar Kalantar-Zadeh  Kidney International 
The DOPPS Practice Monitor for US Dialysis Care: Update on Trends in Anemia Management 2 Years Into the Bundle  Douglas S. Fuller, MS, Ronald L. Pisoni,
Journal of Renal Nutrition
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
2013 Annual Report - 36th Edition
Recent experience with high-dose intravenous iron administration
Chapter 7 Nutritional status on dialysis
Volume 55, Issue 5, Pages (May 1999)
Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry  Takayuki Hamano, Naohiko Fujii, Terumasa.
Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation  A.K. Singh, D.W. Coyne,
CHAPTER 10 Hepatitis on Dialysis
Stock and Flow of Peritoneal Dialysis Patients Australia
Stock and Flow of Haemodialysis Patients Australia
Presentation transcript:

MANAGEMENT OF ANAEMIA IN PATIENTS ON DIALYSIS Philip N. Jeremiah Bee Boon Cheak Ghazali B Ahmad Lim Soo Kun Zawawi B Nordin Source: 20 th MDTR Report 2012, NRR

Table 6.1.1: Treatment for anaemia, HD patients Year Number of patients % on ESAs % received blood transfusion % on oral iron % received parenteral iron Source: 20 th MDTR Report 2012, NRR

Table 6.1.2: Treatment for anaemia, PD patients Year Number of patients % on ESAs % received blood transfusion % on oral iron % received parenteral iron Source: 20 th MDTR Report 2012, NRR

Table 6.1.3: Variation in Erythropoiesis-Stimulating Agents (ESAs) utilization (% patients) among HD centres, Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.1.3(a): Variation in ESAs utilization (% patients) among HD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Figure 6.1.3(b): Median of ESA utilisation (% patients) among HD centres, Source: 20 th MDTR Report 2012, NRR

Table 6.1.4: Variation in ESAs utilization (% patients) among PD centres, Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.1.4(a): Variation in ESAs utilization (% patients) among PD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Figure 6.1.4(b): Median of ESA utilisation (% patients) among PD centres, Source: 20 th MDTR Report 2012, NRR

Table 6.1.5: Variation in mean weekly ESAs dose (u/week) among HD centres, Year Number of centres MeanSDMin 5 th centile LQ Media n UQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.1.5(a): Variation in mean weekly ESAs dose (u/week) among HD centres 2012 Source: 20 th MDTR Report 2012, NRR

Figure 6.1.5(b): Median of mean weekly ESAs dose (u/week) among HD centres, Source: 20 th MDTR Report 2012, NRR

Table 6.1.6: Variation in mean weekly ESAs dose (u/week) among PD centres, Year Number of centres MeanSDMin 5 th centile LQ Media n UQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.1.6(a): Variation in mean weekly ESAs dose (u/week) among PD centres 2012 Source: 20 th MDTR Report 2012, NRR

Figure 6.1.6(b): Median of mean weekly ESAs dose (u/week) among PD centres, Source: 20 th MDTR Report 2012, NRR

Table 6.1.7: Variation in use of blood transfusion (% patients) among HD centres, Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.1.7(a): Variation in use of blood transfusion (% patients) among HD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Figure 6.1.7(b): Median of use of blood transfusion (% patients) among HD centres, Source: 20 th MDTR Report 2012, NRR

Table 6.1.8: Variation in use of blood transfusion (% patients) among PD centres, Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.1.8(a): Variation in use of blood transfusion (% patients) among PD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Figure 6.1.8(b): Median of use of blood transfusion (% patients) among PD centres, Source: 20 th MDTR Report 2012, NRR

Table 6.2.1: Distribution of serum ferritin without ESAs, HD patients Year Number of patients MeanSDMedianLQUQ % Patients ≥100 ng/ml % Patients ≥200 ng/ml Source: 20 th MDTR Report 2012, NRR

Figure 6.2.1: Cumulative Distribution of serum ferritin without ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.2: Distribution of serum ferritin without ESAs, PD patients YearNumber of patientsMeanSDMedianLQUQ % Patients ≥100 ng/ml % Patients ≥200 ng/ml Source: 20 th MDTR Report 2012, NRR

Figure 6.2.2: Distribution of serum ferritin without ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.3: Distribution of serum ferritin on ESAs, HD patients Year Number of patients MeanSDMedianLQUQ % Patients ≥100 ng/ml % Patients ≥200 ng/ml Source: 20 th MDTR Report 2012, NRR

Figure 6.2.3: Cumulative distribution of serum ferritin on ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.4: Distribution of serum ferritin on ESAs, PD patients Year Number of patients MeanSDMedianLQUQ % Patients ≥100 ng/ml % Patients ≥200 ng/ml Source: 20 th MDTR Report 2012, NRR

Figure 6.2.4: Cumulative distribution of serum ferritin on ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.5: Distribution of transferrin saturation without ESAs, HD patients, Year Number of patients MeanSDMedianLQUQ % Patients ≥20 % Source: 20 th MDTR Report 2012, NRR

Figure 6.2.5: Cumulative distribution of transferrin saturation without ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.6: Distribution of transferrin saturation without ESAs, PD patients, Year Number of patients MeanSDMedianLQUQ % Patients ≥20 % Source: 20 th MDTR Report 2012, NRR

Figure 6.2.6: Cumulative distribution of transferrin saturation without ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.7: Distribution of transferrin saturation on ESAs, HD patients, Year Number of patients MeanSDMedianLQUQ % Patients ≥20 % Source: 20 th MDTR Report 2012, NRR

Figure 6.2.7: Cumulative distribution of transferrin saturation on ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.8: Distribution of transferrin saturation on ESAs, PD patients, Year Number of patients MeanSDMedianLQUQ % Patients ≥20 % Source: 20 th MDTR Report 2012, NRR

Figure 6.2.8: Cumulative distribution of transferrin saturation on ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.2.9(a): Variation in Medium serum ferritin among patients on ESAs, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.2.9(a): Variation in medium serum ferritin among patients on ESAs, HD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.2.9(b): Proportion of patients on ESAs with serum ferritin ≥100 ng/ml, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.2.9(a): Variation in medium serum ferritin among patients on ESAs, HD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.2.9(b): Proportion of patients on ESAs with serum ferritin ≥100 ng/ml, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.2.9(b): Variation in proportion of patients on ESAs with serum ferritin ≥ 100 ng/ml, HD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.2.9(c): Median transferrin saturation among patients on ESAs, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.2.9(c): Variation in median transferring saturation among patients on ESAs HD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.2.9(d): Proportion of patients on ESAs with transferrin saturation ≥ 20%, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.2.9(d): Variation in proportion of patients on ESAs with transferring saturation ≥ 20%, HD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Table (a): Variation in medium serum ferritin among patients on ESAs, PD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure (a): Variation in medium serum ferritin among patients on ESAs, PD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table (b): Proportion of patients on ESAs with serum ferritin ≥100 ng/ml, PD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure (b): Variation in proportion of patients on ESAs with serum ferritin ≥ 100ng/ml, PD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table (c): Median transferrin saturation among patients on ESAs, PD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure (c): Variation in median transferrin saturation among patients on ESAs, PD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table (d): Proportion of patients on ESAs with transferring saturation ≥ 20%, PD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure (d): Variation in proportion of patients on ESAs with transferrin saturation ≥ 20 %, PD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.3.1: Distribution of haemoglobin concentration without ESAs, HD patients Year Number of patients MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.1(a): Cumulative distribution of haemoglobin concentration without ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.1(b): Mean of haemoglobin concentration without ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.2: Distribution of haemoglobin concentration without ESAs, PD patients Year Number of patients MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.2(a): Cumulative distribution of haemoglobin concentration without ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.2(b): Mean of haemoglobin concentration without ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.3(a): Distribution of haemoglobin concentration on ESAs, diabetes HD patients Year Number of patients MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.3(a)(i): Cumulative distribution of haemoglobin concentration on ESAs, diabetes HD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.3(a)(ii): Mean of haemoglobin concentration on ESAs, diabetes HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.3(b): Distribution of haemoglobin concentration on ESAs, non-diabetes HD patients Year Number of patients MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.3(b)(i): Cumulative distribution of haemoglobin concentration on ESAs, non-diabetes HD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.3(b)(ii): Mean of haemoglobin concentration on ESAs, non- diabetes HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.4(a): Distribution of haemoglobin concentration on ESAs, diabetes PD patients Year Number of subject MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.4(a)(i): Cumulative distribution of haemoglobin concentration on ESAs, diabetes PD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.4(a)(ii): Mean of haemoglobin concentration on ESAs, diabetes PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.4(b): Distribution of haemoglobin concentration on ESAs, non-diabetes PD patients Year Number of subject MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.4(b)(i): Cumulative distribution of haemoglobin concentration on ESAs, non-diabetes PD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.4(b)(ii): Mean of haemoglobin concentration on ESAs, non- diabetes PD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.5(a): Proportion in median haemoglobin level among patients on ESAs, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.3.5(a): Variation in median haemoglobin level among patients on ESAs, HD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.3.5(b): Proportion of patients on ESAs with haemoglobin level > 10g/dL, HD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.3.5(b): Variation in proportion of patients on ESAs with haemoglobin level > 10g/dL, HD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.3.6(a): Proportion in Median haemoglobin level among patients on ESAs, PD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.3.6(a): Variation in median haemoglobin level among patients on ESAs, PD centres 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.3.6(b): Proportion of patients on ESAs with haemoglobin level > 10g/dL, PD centres Year Number of centres Min 5 th centile LQMedianUQ 95 th centile Max Source: 20 th MDTR Report 2012, NRR

Figure 6.3.6(b): Variation in proportion of patients on ESAs with haemoglobin level > 10g/dL, PD centres, 2012 Source: 20 th MDTR Report 2012, NRR

Table 6.3.7: Distribution of haemoglobin concentration on ESAs, HD patients Year Number of patients MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.7(a): Cumulative distribution of haemoglobin concentration on ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.7(b): Mean of haemoglobin concentration on ESAs, HD patients Source: 20 th MDTR Report 2012, NRR

Table 6.3.8: Distribution of haemoglobin concentration on ESAs, PD patients Year Number of subject MeanSDMedianLQUQ % Patients <10g/dL % Patients 10-<12g/dL % Patients >=12g/dL Source: 20 th MDTR Report 2012, NRR

Figure 6.3.8(a): Cumulative distribution of haemoglobin concentration on ESAs, PD patients Source: 20 th MDTR Report 2012, NRR

Figure 6.3.8(b): Mean of haemoglobin concentration on ESAs, PD patients Source: 20 th MDTR Report 2012, NRR